Anavex Life Sciences reports positive clinical trial data and advancements in various programs

From GlobeNewswire: 2024-08-06 07:30:00

Anavex Life Sciences Corp. reported financial results for the quarter ended June 30, 2024, showcasing positive clinical trial data for blarcamesine in Alzheimer’s disease and advancements in schizophrenia, Parkinson’s disease, Rett syndrome, and Fragile X programs. Key highlights include submission of Marketing Authorization application to the EMA for blarcamesine in Alzheimer’s disease and initiation of various Phase 2/3 trials. The company also presented successful preclinical results at conferences. Financially, the company reported cash and equivalents of $138.8 million, with a net loss of $12.2 million for the quarter. Anavex is dedicated to developing innovative treatments for diverse CNS disorders and rare diseases.



Read more at GlobeNewswire:: Anavex Life Sciences Reports Fiscal 2024 Third Quarter